Gene Delivery

Invitrogen introduces Lipofectamine LTX; reagent improves DNA delivery and lowers toxicity

Published in Gene Therapy Weekly, September 28th, 2006

Invitrogen Corp. (IVGN), a provider of technologies for disease research and drug discovery, introduced a key new product into its successful line of transfection reagents, Lipofectamine LTX.

Lipofectamine LTX, according to the company, provides highly effective delivery of DNA into a wide range of cell types and a significantly lower toxicity profile.

Lipofectamine LTX Reagent effectively delivers DNA into the cell, the first critical step in characterizing gene function, and demonstrates high levels of transfection efficiency and protein expression with more than 90% viability for a wide range of cells, including primary neuronal cells and other...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-09-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry